Homepage Top Section1

Following expansion, the site will cover over 200,000ft² and feature new technologies in sustainably designed facilities. The initial phase of expansion comprises a 31,000ft² building that will accommodate

The collaboration aims to clarify the underlying mechanism of action of iQ-007. The results will assist in stratifying and identifying patients who may benefit from this astrocyte-targeted therapy,

The funding will facilitate the establishment of Nilo’s laboratories in New York City, the growth of the team, and the advancement of preclinical programmes. Furthermore, the company has appointed

Currently, there are no approved treatments for CIAS, a key feature of the condition that significantly affects daily functioning and the quality of life for individuals living with

The total capital raised by the company now stands at $446m, following a $386m series A/A-1 financing announced in November 2024. The series B round was led by

The Boston-based company secured backing from existing investors and new investors, including Affinity Asset Advisors, Dimension Capital, Jeito Capital, Lightspeed Ventures, TPG Life Sciences Innovations, and Wedbush Healthcare

This therapy is aimed at addressing vision loss in children with this disease, a rare paediatric neurodegenerative disorder for which there is currently no treatment available for its

This is a rare and aggressive form of cancer for which there is no approved treatment currently. Aldeyra president and CEO Todd Brady said: “Primary vitreoretinal lymphoma is

The therapy is intended for the treatment of Duchenne muscular dystrophy (DMD) in patients aged four years and above. Sales are projected to begin on a named patient